MA39427B1 - Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète - Google Patents

Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète

Info

Publication number
MA39427B1
MA39427B1 MA39427A MA39427A MA39427B1 MA 39427 B1 MA39427 B1 MA 39427B1 MA 39427 A MA39427 A MA 39427A MA 39427 A MA39427 A MA 39427A MA 39427 B1 MA39427 B1 MA 39427B1
Authority
MA
Morocco
Prior art keywords
gpr40
pyrrolidine
diabetes
diseases
treatment
Prior art date
Application number
MA39427A
Other languages
English (en)
French (fr)
Other versions
MA39427A1 (fr
Inventor
Elizabeth A Jurica
Zhenqiu Hong
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA39427A1 publication Critical patent/MA39427A1/fr
Publication of MA39427B1 publication Critical patent/MA39427B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA39427A 2014-05-07 2015-05-06 Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète MA39427B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461989651P 2014-05-07 2014-05-07
PCT/US2015/029409 WO2015171722A1 (en) 2014-05-07 2015-05-06 Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

Publications (2)

Publication Number Publication Date
MA39427A1 MA39427A1 (fr) 2017-11-30
MA39427B1 true MA39427B1 (fr) 2018-09-28

Family

ID=53181359

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39427A MA39427B1 (fr) 2014-05-07 2015-05-06 Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète

Country Status (33)

Country Link
US (4) US9873679B2 (enExample)
EP (1) EP3140296B1 (enExample)
JP (1) JP6483156B2 (enExample)
KR (1) KR102336370B1 (enExample)
CN (1) CN106458976B (enExample)
AR (1) AR100328A1 (enExample)
AU (1) AU2015256120B2 (enExample)
BR (1) BR112016024936A2 (enExample)
CA (1) CA2948161C (enExample)
CL (1) CL2016002809A1 (enExample)
CY (1) CY1120340T1 (enExample)
DK (1) DK3140296T3 (enExample)
EA (1) EA033250B1 (enExample)
ES (1) ES2674531T3 (enExample)
HR (1) HRP20180641T1 (enExample)
HU (1) HUE039288T2 (enExample)
IL (1) IL248668B (enExample)
MA (1) MA39427B1 (enExample)
MX (1) MX378160B (enExample)
MY (1) MY181959A (enExample)
NZ (1) NZ727146A (enExample)
PE (1) PE20161363A1 (enExample)
PH (1) PH12016502034B1 (enExample)
PL (1) PL3140296T3 (enExample)
PT (1) PT3140296T (enExample)
RS (1) RS57170B1 (enExample)
SG (1) SG11201609170UA (enExample)
SI (1) SI3140296T1 (enExample)
SM (1) SMT201800342T1 (enExample)
TN (1) TN2016000444A1 (enExample)
TR (1) TR201809633T4 (enExample)
TW (1) TWI659951B (enExample)
WO (1) WO2015171722A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016024936A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
BR112016025188A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de pirrolidina gpr40 para o tratamento de doenças tal como diabetes
CA3041038A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
JP7086942B2 (ja) 2016-09-12 2022-06-20 インテグラル ヘルス， インコーポレイテッド Ｇｐｒ１２０モジュレーターとして有用な単環式化合物
CN110719903A (zh) * 2017-03-31 2020-01-21 武田药品工业株式会社 芳族环化合物
CN110947003B (zh) * 2017-08-21 2021-04-02 武汉大学 Gpr31抑制剂在制备治疗肾脏缺血再灌注损伤及相关疾病药物中的应用
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202317534A (zh) 2021-06-16 2023-05-01 美商西建公司 用於治療神經退化性疾病之含羧酸吖丁啶基化合物
CN116283699B (zh) * 2023-03-02 2025-02-11 遵义医科大学 一种合成氟烷基取代的吡咯烷的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP2486005B1 (en) * 2009-10-06 2014-06-18 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
US7939569B1 (en) * 2009-12-01 2011-05-10 Hoffmann-La Roche Inc. Aniline analogs as glycogen synthase activators
GB2498976A (en) * 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
WO2014022253A1 (en) 2012-08-01 2014-02-06 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
EP2925726B1 (en) 2012-11-16 2016-10-26 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
SG11201503556PA (en) 2012-11-16 2015-06-29 Bristol Myers Squibb Co Dihydropyrazole gpr40 modulators
EA026913B1 (ru) 2012-11-16 2017-05-31 Бристол-Майерс Сквибб Компани Дигидропиразольные модуляторы gpr40
AU2013344603B2 (en) * 2012-11-16 2017-07-06 Bristol-Myers Squibb Company Pyrrolidine GPR40 modulators
WO2015171757A1 (en) 2014-05-07 2015-11-12 Bristol-Myers Squibb Company Pyrrolidine gpr40 modulators
BR112016024936A2 (pt) * 2014-05-07 2017-08-15 Bristol Myers Squibb Co moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
SG11201608402WA (en) 2014-05-07 2016-11-29 Croma Pharma Ges M B H Aqueous ophthalmic solution and method for treating dry eye syndrome

Also Published As

Publication number Publication date
SMT201800342T1 (it) 2018-09-13
PH12016502034B1 (en) 2022-03-23
CY1120340T1 (el) 2019-07-10
PE20161363A1 (es) 2016-12-17
IL248668A0 (en) 2017-01-31
US20150322044A1 (en) 2015-11-12
JP2017514856A (ja) 2017-06-08
CA2948161A1 (en) 2015-11-12
NZ727146A (en) 2020-01-31
JP6483156B2 (ja) 2019-03-13
KR102336370B1 (ko) 2021-12-06
PH12016502034A1 (en) 2017-01-09
MX2016013801A (es) 2017-03-09
HUE039288T2 (hu) 2018-12-28
RS57170B1 (sr) 2018-07-31
EA033250B1 (ru) 2019-09-30
PL3140296T3 (pl) 2018-08-31
TR201809633T4 (tr) 2018-07-23
BR112016024936A2 (pt) 2017-08-15
HRP20180641T1 (hr) 2018-06-01
US20190112293A1 (en) 2019-04-18
AU2015256120B2 (en) 2019-03-28
TWI659951B (zh) 2019-05-21
CN106458976A (zh) 2017-02-22
TW201625585A (zh) 2016-07-16
MY181959A (en) 2021-01-15
CN106458976B (zh) 2020-05-22
US20200299267A1 (en) 2020-09-24
EP3140296A1 (en) 2017-03-15
SG11201609170UA (en) 2016-12-29
SI3140296T1 (en) 2018-06-29
US9873679B2 (en) 2018-01-23
MA39427A1 (fr) 2017-11-30
MX378160B (es) 2025-03-10
AR100328A1 (es) 2016-09-28
CL2016002809A1 (es) 2017-03-24
IL248668B (en) 2019-09-26
DK3140296T3 (en) 2018-07-23
KR20160147049A (ko) 2016-12-21
CA2948161C (en) 2020-10-27
EP3140296B1 (en) 2018-04-11
TN2016000444A1 (en) 2018-04-04
EA201692037A1 (ru) 2017-06-30
US10717725B2 (en) 2020-07-21
ES2674531T3 (es) 2018-07-02
US20180099949A1 (en) 2018-04-12
PT3140296T (pt) 2018-06-27
AU2015256120A1 (en) 2016-12-22
WO2015171722A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
MA39427A1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA39088A1 (fr) Compositions et procédés pour moduler des récepteurs farnesoïde x
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
EA201792515A1 (ru) ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОХИНОЛИНОНА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕТИНОИДНЫХ ОРФАНОВЫХ РЕЦЕПТОРОВ ГАММА (RORγ)
EA201791017A1 (ru) Гидроксисодержащие соединения, модулирующие fxr (nr1h4)
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
MA40302B1 (fr) Dérivés de carbazole
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
MX378158B (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139).
MA41041A (fr) Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii
EA202091428A1 (ru) Замещенные амиды ii пирролидина
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
EA202091429A1 (ru) Замещенные амиды i пирролидина
MA39950B1 (fr) Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
EA202092146A1 (ru) Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MX2016014118A (es) Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes.
MA43231B1 (fr) Bloqueur des canaux sodiques
MA46965B1 (fr) Modulateurs de gamma ror (rory)